$266 Million is the total value of RTW INVESTMENTS, LP's 32 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 47.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALNY | Sell | Alnylam Pharmaceuticals Inc | $29,548,000 | -54.0% | 789,208 | -16.8% | 11.12% | -42.7% |
| BCRX | Sell | Biocryst Pharmaceuticals | $25,819,000 | +39.2% | 4,078,895 | -3.0% | 9.72% | +73.4% |
| LJPC | Sell | La Jolla Pharmaceutical Co | $19,038,000 | -31.6% | 1,086,037 | -7.2% | 7.17% | -14.8% |
| INCY | Sell | Incyte Corp | $8,699,000 | -51.7% | 86,757 | -54.6% | 3.27% | -39.9% |
| OMER | Sell | Omeros Corp | $2,570,000 | -39.9% | 259,039 | -32.4% | 0.97% | -25.2% |
| ACHN | Sell | Achillion Pharmaceuticals In | $1,182,000 | -93.4% | 286,285 | -87.0% | 0.44% | -91.8% |
| CLDX | Sell | Celldex Therapeutics Inc New | $848,000 | -83.1% | 239,662 | -80.7% | 0.32% | -79.0% |
| SRTS | Sell | Sensus Heatlhcare Inc | $645,000 | -16.6% | 122,803 | -2.3% | 0.24% | +3.8% |
| GBT | Sell | Global Blood Therapeutics In | $375,000 | -83.0% | 25,963 | -72.9% | 0.14% | -78.9% |
| ABEO | Exit | Abeona Therapeutics Inc | $0 | – | -19,391 | -100.0% | -0.04% | – |
| NVAX | Exit | NOVAVAX INCcall | $0 | – | -4,787 | -100.0% | -0.30% | – |
| FPRX | Exit | Five Prime Therapeutics Inc | $0 | – | -44,044 | -100.0% | -0.70% | – |
| JJOFF | Exit | Barclays Bank Plcetn djubscoffe38 | $0 | – | -180,500 | -100.0% | -1.21% | – |
| HRTX | Exit | Heron Therapeutics Inc | $0 | – | -386,787 | -100.0% | -2.01% | – |
| ARWR | Exit | Arrowhead Pharmaceuticals Inc | $0 | – | -1,116,777 | -100.0% | -2.48% | – |
| Exit | Atara Biotherapeutics Inc. | $0 | – | -458,113 | -100.0% | -2.96% | – | |
| GLD | Exit | SPDR Gold Trust | $0 | – | -83,000 | -100.0% | -3.15% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.